NTS071 to Target p53 Y220C Mutation in Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: APG-5918 an EED Inhibitor for Prostate Cancer Therapy
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: CTS2190 Targets Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 trial: SYN818 Shows Promise for Prostate Cancer Patients With HRR Genetic Mutations
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: NXP900 for Overcoming Resistance in Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Recruiting: ABBV-969, A Novel Bispecific Antibody Drug Conjugate for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: GDC-2992, A Novel Dual-Action AR Degrader Aiming to Overcome Resistance in Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Recruiting: IMP1734 (EIK1003), A New PARP1 Inhibitor for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Recruiting: GSK5764227 Targets B7-H3 in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025
- Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors June 5, 2025
- UPDATE About ACE-232: Phase 1 Trial of a Novel CYP11A1 Inhibitor for mCRPC June 5, 2025